XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Ebola Channel
subscribe to Ebola newsletter

Latest Research : Infectious Diseases : Ebola

   DISCUSS   |   EMAIL   |   PRINT
Ebola Virus Vaccine May Protect Against Sudan and Zaire Species
Mar 11, 2006, 20:37, Reviewed by: Dr. Priya Saxena

"To our knowledge, this is the first demonstration of a bivalent EBOV vaccine to coexpress multiple serotype proteins in a single vaccine construct, eliciting efficient humoral and cellular immune responses to both SEBOV and ZEBOV antigens,"

 
Researchers from South Carolina and Maryland have developed a bivalent vaccine that may protect against both the Sudan and Zaire species of Ebola virus. Their findings appear in the March 2006 issue of the Journal of Virology.

Ebola virus (EBOV) causes a severe hemorrhagic fever in humans and nonhuman primates resulting in death in 90% of those infected. Two particular species, Sudan ebolavirus (SEBOV) and Zaire ebolavirus (ZEBOV), have been responsible for the deadly human outbreaks that have occurred in Africa. To date, outbreaks have been limited to this region, however increasing international travel and bioterrorist threats have reinforced the need for an effective and swift acting vaccine.

In the study researchers vaccinated mice with a bivalent vaccine, containing both SEBOV and ZEBOV genes, and found that vaccination led to efficient induction of EBOV antibody and immune responses to both species. In addition, a group of immunized mice were challenged with a lethal dose of ZEBOV and the survival rate was 100%.

"To our knowledge, this is the first demonstration of a bivalent EBOV vaccine to coexpress multiple serotype proteins in a single vaccine construct, eliciting efficient humoral and cellular immune responses to both SEBOV and ZEBOV antigens," say the researchers.
 

- D. Wang, N.U. Raja, C.M. Trubey, L.Y. Juompan, M. Luo, J. Woraratanadharm, S.B. Deitz, H. Yu, B.M. Swain, K.V. Moore, W.D. Pratt, M.K. Hart, J.Y. Dong. 2006. Development of a cAdVax-based bivalent Ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. Journal of Virology, 80. 6: 2738-2746
 

www.asm.org

 
Subscribe to Ebola Newsletter
E-mail Address:

 



Related Ebola News

How Ebola and Marburg viruses cause disease
Simplified vaccine against Ebola virus developed
Ebola Virus Vaccine May Protect Against Sudan and Zaire Species
Ebola DNA vaccine produces immune responses : Phase 1 trial
Charting the Path of the Deadly Ebola (ZEBOV) Virus
Scientists discover how Ebola virus infects cells


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us